• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer--a phase I toxicity study and pharmacokinetic analysis.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Prendiville, Joseph A
    Thatcher, Nick
    Lind, Michael J
    McIntosh, R
    Ghosh, Anna K
    Stern, Peter L
    Crowther, Derek
    Affiliation
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, U.K.
    Issue Date
    1993
    
    Metadata
    Show full item record
    Abstract
    19 patients with advanced cancer were entered into a phase I study of recombinant human interleukin-4 (rhu IL-4). The predominant clinical side-effects included flu-like symptoms, gastrointestinal upset, lethargy and transient hypotension. In addition, there were several cases of capillary leak syndrome. 2 cases of gastrointestinal haemorrhage occurred; this was life threatening in 1 patient. The maximum tolerated dose (MTD) was 400 micrograms/m2/day. Biochemical toxicity was limited to asymptomatic elevation of liver enzymes suggesting IL-4 induced liver damage. Pharmacokinetic analysis following the intravenous bolus injection has shown that IL-4 is rapidly cleared (mean T1/2 = 19 +/- 8.7 min) from a small compartment (mean Vd = 4.9 +/- 3.68 l) probably indicating that IL-4 is retained in the systemic circulation or at most the extracellular fluid volume. 2 patients with non-Hodgkin lymphomas (NHL) showed a transient response to IL-4 whilst a third patient with NHL showed transient disease progression.
    Citation
    Recombinant human interleukin-4 (rhu IL-4) administered by the intravenous and subcutaneous routes in patients with advanced cancer--a phase I toxicity study and pharmacokinetic analysis. 1993, 29A (12):1700-7 Eur. J. Cancer
    Journal
    European Journal of Cancer
    URI
    http://hdl.handle.net/10541/99920
    DOI
    10.1016/0959-8049(93)90108-R
    PubMed ID
    8398297
    Type
    Article
    Language
    en
    ISSN
    0959-8049
    ae974a485f413a2113503eed53cd6c53
    10.1016/0959-8049(93)90108-R
    Scopus Count
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia.
    • Authors: Bernstein SH, Fay J, Frankel S, Christiansen N, Baer MR, Jacobs C, Blosch C, Hanna R, Herzig G
    • Issue date: 1999
    • Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy.
    • Authors: Atkins MB, Vachino G, Tilg HJ, Karp DD, Robert NJ, Kappler K, Mier JW
    • Issue date: 1992 Nov
    • A phase I study of recombinant human interleukin-4 administered by the intravenous and subcutaneous route in patients with advanced cancer: immunological studies.
    • Authors: Ghosh AK, Smith NK, Prendiville J, Thatcher N, Crowther D, Stern PL
    • Issue date: 1993 May-Jun
    • A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer.
    • Authors: Davis ID, Maher DW, Cebon JS, Green MD, Fox RM, McKendrick JJ, Rybak ME, Boyd AW
    • Issue date: 2000
    • Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    • Authors: Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML
    • Issue date: 1997 Mar
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.